137 Results
Sort By:
Published on April 27, 2022
Knowing whether chemotherapy has been successful in treating cancer is always critical, especially in the case of bladder cancer in which treatment failure often leads to radical cystectomy, or bladder removal surgery. Experienced physicians are able to make that determination. Now, a new machine learning tool has been created to…
Published on April 13, 2022
Leukemia Non-Responders to CAR-T Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results from researchers at the National Cancer Institute (NCI) “We identified a signature of nonresponse that is…
Published on September 23, 2021
Results from an open-label Phase III study show that UK biotech Immunocore’s T-cell receptor therapy tebentafusp significantly improved overall survival of patients with metastatic uveal melanoma versus standard treatment. T-cell receptor (TCR) therapies are a new class of immunotherapy that “use an engineered high-affinity T-cell receptor to target any protein,…
Published on June 3, 2021
Researchers at the Francis Crick Institute have uncovered a protein that aids tumors to evade the immune system and is a likely candidate as a new immunotherapy target. Their findings are published in the journal Cell in a paper titled, “Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity.” “Cross-presentation of antigens from…
Published on August 4, 2020
Cancer patients who have low levels of circulating tumor (ct)DNA before starting treatment with immunotherapy are more likely to have a positive response to the treatment, according to research from the University of Toronto. The scientists also tested whether changes in ctDNA during treatment could reflect whether patients would have…
Published on June 25, 2020
GNS Healthcare, a precision medicine company leveraging artificial intelligence to model individual patients’ response to drug treatment, have unveiled the first in silico multiple myeloma patient. Called Gemini, the in silico multiple myeloma patient is a computer model of disease progression and drug response at the individual patient level. The…
Published on June 15, 2020
As the field of precision medicine matures, it requires evermore technological improvements across a broader base of disciplines. Our list of half-a-dozen companies that are providing innovative solutions is no exception. From new applications of NGS and non-invasive testing, to leveraging technology to handle disparate datasets and solve genetic counseling…
Published on April 1, 2020
Thyroid dysfunction following cancer treatment with immune checkpoint inhibitors is more common than previously thought, according to research accepted for presentation at the Endocrine Society’s annual meeting (which was cancelled), and soon to be published in a special supplemental section of the Journal of the Endocrine Society. Cancer immunotherapy, particularly treatment…
Published on March 24, 2020
As the market for immunotherapies grows, reaching over $10 billion already, the interest in biomarkers to guide prescribing has intensified. Doctors want better ways to predict who will benefit from the drugs. “We need to protect patients from unnecessary risk of side effects from drugs that can’t help them and…
Published on March 5, 2020
The field of genomics has made fantastic progress in the fields of biomedical research and clinical development. This is good news for patients and excellent news for investors, as the field of genomics is expected to pay large dividends in finance in the coming decade. Despite being a relatively new…
Published on January 16, 2020
As immune checkpoint inhibitor drugs have shown spectacular results in some patients, while other patients show little or no response, the race is on to develop biomarkers of immune activity that can help identify responders from non-responders. Now, a team of investigators at Johns Hopkins Kimmel Cancer Center, the Bloomberg-Kimmel Institute…
Published on November 6, 2019
Promega said today it will develop its microsatellite instability (MSI) technology as an on-label, solid tumor companion diagnostic (CDx) to Merck’s blockbuster cancer immunotherapy Keytruda (pembrolizumab), through a global collaboration whose value was not disclosed. Promega’s MSI testing is designed to functionally measure the genomic accumulation of insertion or deletion…
Published on July 18, 2019
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark (since acquired by Agilent Technologies) received authorization to market HercepTest. The immunohistochemistry (IHC) assay was designed to detect human epidermal growth factor receptor 2 (HER2) protein…
Published on June 6, 2019
A new compound has been discovered that disables a key DNA repair pathway involved In cancer drug resistance. The potential drug, found by researchers at MIT and Duke University, enhances the effects of cisplatin, a popular cancer chemotherapy. The paper appears in the June 6 issue of Cell. Cisplatin is a…
Published on March 25, 2019
GlaxoSmithKline (GSK)’s recently announced $4.2 billion partnership to co-develop and co-commercialize Merck KGaA, Darmstadt’s cancer immunotherapy candidate M7824 was a reminder of just how much biopharma giants are willing to invest in a therapeutic area that has generated sometimes-dazzling results. How high is up for immuno-oncology? Numerous firms have ventured their best…